# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Goldman Sachs analyst Paul Choi maintains PTC Therapeutics (NASDAQ:PTCT) with a Sell and raises the price target from $18 to...
- Review of European marketing application for PKU now initiated -WARREN, N.J., May 28, 2024 /PRNewswire/ -- PTC Therapeutics, ...
Citigroup analyst David Lebowitz maintains PTC Therapeutics (NASDAQ:PTCT) with a Sell and raises the price target from $18 t...
JP Morgan analyst Eric Joseph maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $4...
Goldman Sachs analyst Paul Choi maintains PTC Therapeutics (NASDAQ:PTCT) with a Sell and raises the price target from $18 to...
-Reuters
Jefferies analyst Kelly Shi maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $35 to $46.
PTC Therapeutics announced that the European Commission has asked the CHMP to re-evaluate its negative opinion on the renewal o...